Abstract:BACKGROUND/AIMS: Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that binds to the antioxidant response element(s) (ARE) in target gene promoters, enabling oxidatively stressed cells to respond in order to restore redox homeostasis. Post-translational modifications (PTMs) that mediate activation of Nrf2, in the cytosol and its release from Keap1, have been extensively studied but PTMs that impact its biology after activation are beginning to emerge. In this regard, PTMs like acetylation, phosphorylation, ubiquitination and sumoylation contribute towards the Nrf2 subcellular localization, and its transactivation function. We previously demonstrated that Nrf2 traffics to the promyelocytic leukemia-nuclear bodies (PML-NB), where it is a target for modification by small ubiquitin-like modifier (SUMO) proteins (sumoylation), but the site(s) for SUMO conjugation have not been determined. In this study, we aim to identify SUMO-2 conjugation site(s) and explore the impact, sumoylation of the site(s) have on Nrf2 stability, nuclear localization and transcriptional activation of its target gene expression upon oxidative stress. METHODS: The putative SUMO-binding sites in Nrf2 for human isoform1 (NP_006155.2) and mouse homolog (NP_035032.1) were identified using a computer-based SUMO-predictive software (SUMOplotTM). Site-directed mutagenesis, immunoblot analysis, and ARE-mediated reporter gene assays were used to assess the impact of sumoylation on these site(s) in vitro. Effect of mutation of these sumoylation sites of Nrf2 on expression of Heme Oxygenase1 (HO-1) was determined in HEK293T cell. RESULTS: Eight putative sumoylation sites were identified by SUMOplotTM analysis. Out of the eight predicted sites only one 532LKDE535 of human (h) and its homologous 524LKDE527 of mouse (m) Nrf2, exactly matches the SUMO-binding consensus motif. The other high probability SUMO-acceptor site identified was residue K110, in the motifs 109PKSD112 and 109PKQD112 of human and mouse Nrf2, respectively. Mutational analysis of putative sumoylation sites (human (h)/mouse (m) K110, hK533 andmK525)showed that these residues are needed for SUMO-2 conjugation, nuclear localization and ARE driven transcription of reporter genes and the endogenous HO-1 expression by Nrf2. These residues also stabilized Nrf2, as evident from shorter half-lives of the mutant protein compared to wild-type Nrf2. CONCLUSION: Our findings indicate that SUMO-2 mediated sumoylation of K110 and K533 in human Nrf2 regulates in part its transcriptional activity by enhancing its stabilization and nuclear localization.

SUMOylation of the Ubiquitin Ligase Component KEAP1 at K39 Upregulates NRF2 and Its Target Function in Lung Cancer Cell Proliferation.

Mild Oxidative Stress Reduces NRF2 SUMOylation to Promote <i>Kras</i>/<i>Lkb1</i>/<i>Keap1</i> Mutant Lung Adenocarcinoma Cell Migration and Invasion

Abstract 4061: Depleting the cellular level of glutathione and subsequently S -glutathionylation of keap1 by electrophilic agents activates keap1-nrf2 pathway

Interplay Of Mkp-1 And Nrf2 Drives Tumor Growth And Drug Resistance In Non-Small Cell Lung Cancer

NRF2 SUMOylation Promotes De Novo Serine Synthesis and Maintains HCC Tumorigenesis.

Genome-wide Global Identification of NRF2 Binding Sites in A549 Non-Small Cell Lung Cancer Cells by ChIP-Seq Reveals NRF2 Regulation of Genes Involved in Focal Adhesion Pathways

Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress

Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma

NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer.

Regulatory Role of KEAP1 and NRF2 in PPARγ Expression and Chemoresistance in Human Non-Small-cell Lung Carcinoma Cells.

“NRF2 Addiction” in Lung Cancer Cells and Its Impact on Cancer Therapy

Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer.

Molecular Basis of the KEAP1-NRF2 Signaling Pathway

Luteolin Inhibits Nrf2 Leading to Negative Regulation of the Nrf2/Are Pathway and Sensitization of Human Lung Carcinoma A549 Cells to Therapeutic Drugs

Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks

Role of Human Keap1 S53 and S293 Residues in Modulating the Binding of Keap1 to Nrf2.

Transcriptional Dynamics of NRF2 Overexpression and KEAP1-NRF2 Inhibitors in Human Cell Line and Primary Lung Cells

SUMO-Modification of Human Nrf2 at K110 and K533 Regulates Its Nucleocytoplasmic Localization, Stability and Transcriptional Activity

“Keaping” an Eye on the NRF2 Signature Score: Expanding Its Applicability in Lung Cancer

The deubiquitinating enzyme USP35 regulates the stability of NRF2 protein

NRF2 Activation Induces NADH-reductive Stress, Providing a Metabolic Vulnerability in Lung Cancer